Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia

Schizophrenia Research
D L BraffN R Swerdlow

Abstract

Schizophrenia patients have prominent deficits in information processing that can be detected by measures of prepulse inhibition (PPI) of the startle response. Deficient PPI in schizophrenia is thought to reflect a failure of brain-based information 'protective' mechanisms that normally inhibit responsivity for 30-500ms after a weak prepulse stimulus. The relationship between specific prepulse stimulus characteristics and PPI deficits in this study was examined in 31 schizophrenia patients and 34 normal comparison subjects. Schizophrenia patients had overall deficits in PPI across four conditions where the prepulse was either discrete (abrupt) or continuous (sustained) and consisted of either white noise or a pure tone. On inspection and analysis of the data, it appears that the white noise conditions, rather than tone conditions, account for the group differences. Thus, the discrete white noise prepulse was most effective in eliciting PPI deficits, resulting in a large effect size between groups (d=0.85; P<0.01). Deficits in information-protective mechanisms in schizophrenia may be differentially sensitive to specific stimulus characteristics; this observation may be relevant both to the neurobiology of information processing ...Continue Reading

References

Mar 1, 1992·Archives of General Psychiatry·D L BraffM A Geyer
Jan 1, 1992·Psychophysiology·R F Simons, B D Giardina
Feb 1, 1968·The Journal of the Acoustical Society of America·H S Hoffman, J L Searle
Feb 1, 1981·The American Journal of Psychiatry·K A Kessler, J P Waletzky
Mar 1, 1995·Biological Psychiatry·N R SwerdlowD L Braff
Feb 1, 1995·Journal of Neurology, Neurosurgery, and Psychiatry·N R SwerdlowM R Swenson
Dec 1, 1993·The American Journal of Psychiatry·K S CadenheadD L Braff
Nov 1, 1993·Journal of Abnormal Psychology·M E DawsonA M Schell
Jan 1, 1993·Schizophrenia Bulletin·J M McDowdD L Braff
Jan 1, 1993·Schizophrenia Bulletin·D L Braff
Jan 1, 1996·Biological Psychiatry·F X CastellanosM Hallett
Jan 1, 1996·The Journal of Neuropsychiatry and Clinical Neurosciences·L P KarperJ H Krystal
Jan 21, 1997·Proceedings of the National Academy of Sciences of the United States of America·R FreedmanW Byerley
Apr 4, 2000·Biological Psychiatry·A ParwaniJ P Rotrosen
Jan 1, 1961·The British Journal of Medical Psychology·A MCGHIE, J CHAPMAN

❮ Previous
Next ❯

Citations

Mar 12, 2008·Psychopharmacology·Marco BortolatoRoberto Stancampiano
Oct 10, 2009·Psychopharmacology·Kirsty Elizabeth Scholes, Mathew Thomas Martin-Iverson
Aug 24, 2011·Psychopharmacology·Chisato WakabayashiHiroshi Kunugi
Jul 6, 2011·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Kathleen M GrantRick A Bevins
Mar 20, 2010·Neurotoxicity Research·Trevor ArcherRichard M Kostrzewa
Apr 16, 2004·Behavioural Brain Research·Sidse Marie ArnfredRalf Peter Hemmingsen
Nov 19, 2003·European Journal of Pharmacology·David A Keays, Patrick M Nolan
Dec 31, 2003·Molecular and Cellular Neurosciences·S M HarrisonP R Maycox
Jan 31, 2004·Progress in Neuro-psychopharmacology & Biological Psychiatry·Suzan OzerA Nurten Akarsu
Oct 8, 2004·Schizophrenia Research·Veena KumariTonmoy Sharma
Sep 19, 2006·Psychological Medicine·Jonathan Flint, Marcus R Munafò
Jun 10, 2008·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Stella G GiakoumakiPanos Bitsios
Aug 6, 2010·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Karen M AlseneVaishali P Bakshi
Oct 1, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Eva HradetzkySabine Bahn
Apr 8, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Panos RoussosPanos Bitsios
Aug 27, 2005·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Neal R SwerdlowPamela P Auerbach
Jan 20, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Agnès L AuclairAdrian Newman-Tancredi
Mar 8, 2007·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Ebony R SamuelsChristopher M Bradshaw
Feb 26, 2009·Proceedings of the National Academy of Sciences of the United States of America·Claudia S BarrosUlrich Müller
Apr 19, 2012·Alcohol and Alcoholism : International Journal of the Medical Council on Alcoholism·Albert AcewiczPrzemyslaw Bienkowski
Dec 1, 2006·Schizophrenia Bulletin·Bruce I TuretskyNeal R Swerdlow
Sep 22, 2005·Clinical and Experimental Pharmacology & Physiology·Alexandra E Rehn, Sandra M Rees
Oct 1, 2012·Acta Neuropsychiatrica·Luigia TrabaceVincenzo Cuomo
Jun 19, 2012·The Journal of Clinical Investigation·Hai-Ying ShenDetlev Boison
Jul 26, 2012·PloS One·Jennifer BrielmaierJacqueline N Crawley
Oct 9, 2013·Psychopharmacology·Ana C IssyElaine A Del-Bel

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here